Results 261 to 270 of about 1,230,724 (345)

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

Analysis of admissions with bronchial asthma and chronic obstructive pulmonary disease exacerbations

, 2016
L. Yu. Palmova, A. A. Podolskaya, Z A Shaykhutdinova, Д А Заплатова, E B Druzhkova   +4 more
openalex   +2 more sources

Associations of Community Material Neighborhood Deprivation With the Diagnosis of Asthma Among Infants With Bronchopulmonary Dysplasia (BPD). [PDF]

Pediatr Pulmonol
Szeto JJ, Boom K, Radack JK, DeMauro SB, Kenyon CC, Novick-Goldstein NP, Scott KA, Murosko DC, Gibbs KA, Lorch SA, Moore PE, Burris HH, Nelin TD.   +12 more
europepmc   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

ROLE OF ORAL MONTELUKAST IN ACUTE ASTHMA EXACERBATIONS : A RANDOMIZED PLACEBO CONTROLLED TRIAL

, 2015
Gaude Gajanan, Chaudhury Alisha, Hattiholi Jyothi   +2 more
openalex   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Digitally assessed home FEV₁ to identify the cause of poorly controlled asthma: a protocol paper for a prospective replicate cohort study. [PDF]

BMJ Open Respir Res
Gill CM, Kerr PJ, Ottewill C, Brennan V, Doherty H, Smith O, MacHale E, Cushen B, Ryan D, Greene G, Costello RW.   +10 more
europepmc   +1 more source

Conservation Can Better Integrate Environmental Justice if We Consider People’s Needs

The Bulletin of the Ecological Society of America, EarlyView.
Beck M. Swab
wiley   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Asthma and dental health in children. Review of the literature

, 2013
Radosveta Andreevа, Ani Belcheva, Iliana Giozova   +2 more
openalex   +2 more sources